International Perspectives on the Cost-Effectiveness of Tandem Mass Spectrometry for Rare Metabolic Conditions
Objectives: To examine and evaluate the economic evidence regarding the use of tandem mass spectrometry (MS/MS) for the detection of rare metabolic conditions in neonates, and then to consider the transferability of these national-level results to other decision-making contexts.Methods: A systematic...
| Main Authors: | , , |
|---|---|
| Format: | Journal Article |
| Published: |
Elsevier Ireland Ltd
2009
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/16150 |
| _version_ | 1848749092721655808 |
|---|---|
| author | Norman, Richard Haas, M. Wilcken, B. |
| author_facet | Norman, Richard Haas, M. Wilcken, B. |
| author_sort | Norman, Richard |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Objectives: To examine and evaluate the economic evidence regarding the use of tandem mass spectrometry (MS/MS) for the detection of rare metabolic conditions in neonates, and then to consider the transferability of these national-level results to other decision-making contexts.Methods: A systematic literature review was undertaken, identifying papers published between January 1997 and March 2008. Thirteen unique cost-effectiveness evaluations were identified and appraised forcomparability and transferability of results across settings.Results: The primary outcome measure was usually life years gained (LYG) or quality adjusted lifeyears gained (QALY). The incremental cost-effectiveness ratios (ICER) presented were generally supportive of MS/MS, but showed considerable variation. Differences in assumptions made regarding prevalence and prognosis played a significant role in this variation.Conclusions: Differences in study structure, the approach to costing, the choice of intervention, control and outcome measure, and the limit of studies to developed countries makes international generalisation of the cost-effectiveness evidence difficult. The importance of assumptions regarding disease progression and subsequent health care utilisation suggests that further work needs to consider the importance of longer-term follow-up. |
| first_indexed | 2025-11-14T07:15:27Z |
| format | Journal Article |
| id | curtin-20.500.11937-16150 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T07:15:27Z |
| publishDate | 2009 |
| publisher | Elsevier Ireland Ltd |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-161502017-09-13T15:04:06Z International Perspectives on the Cost-Effectiveness of Tandem Mass Spectrometry for Rare Metabolic Conditions Norman, Richard Haas, M. Wilcken, B. Health economics Cost-effectiveness Review Tandem mass spectrometry Metabolism Objectives: To examine and evaluate the economic evidence regarding the use of tandem mass spectrometry (MS/MS) for the detection of rare metabolic conditions in neonates, and then to consider the transferability of these national-level results to other decision-making contexts.Methods: A systematic literature review was undertaken, identifying papers published between January 1997 and March 2008. Thirteen unique cost-effectiveness evaluations were identified and appraised forcomparability and transferability of results across settings.Results: The primary outcome measure was usually life years gained (LYG) or quality adjusted lifeyears gained (QALY). The incremental cost-effectiveness ratios (ICER) presented were generally supportive of MS/MS, but showed considerable variation. Differences in assumptions made regarding prevalence and prognosis played a significant role in this variation.Conclusions: Differences in study structure, the approach to costing, the choice of intervention, control and outcome measure, and the limit of studies to developed countries makes international generalisation of the cost-effectiveness evidence difficult. The importance of assumptions regarding disease progression and subsequent health care utilisation suggests that further work needs to consider the importance of longer-term follow-up. 2009 Journal Article http://hdl.handle.net/20.500.11937/16150 10.1016/j.healthpol.2008.08.003 Elsevier Ireland Ltd restricted |
| spellingShingle | Health economics Cost-effectiveness Review Tandem mass spectrometry Metabolism Norman, Richard Haas, M. Wilcken, B. International Perspectives on the Cost-Effectiveness of Tandem Mass Spectrometry for Rare Metabolic Conditions |
| title | International Perspectives on the Cost-Effectiveness of Tandem Mass Spectrometry for Rare Metabolic Conditions |
| title_full | International Perspectives on the Cost-Effectiveness of Tandem Mass Spectrometry for Rare Metabolic Conditions |
| title_fullStr | International Perspectives on the Cost-Effectiveness of Tandem Mass Spectrometry for Rare Metabolic Conditions |
| title_full_unstemmed | International Perspectives on the Cost-Effectiveness of Tandem Mass Spectrometry for Rare Metabolic Conditions |
| title_short | International Perspectives on the Cost-Effectiveness of Tandem Mass Spectrometry for Rare Metabolic Conditions |
| title_sort | international perspectives on the cost-effectiveness of tandem mass spectrometry for rare metabolic conditions |
| topic | Health economics Cost-effectiveness Review Tandem mass spectrometry Metabolism |
| url | http://hdl.handle.net/20.500.11937/16150 |